Gateway Biotechnology develops drugs to prevent noise-induced hearing loss (NIHL) and tinnitus. We currently have one drug in phase II clinical trials to prevent NIHL in a project funded by the US Department of the Army and a second drug in pre-clinical development for the same indication. Our lead candidate for tinnitus is at the pre-clinical stage where we are conducting PK and Toxicity studies to transition to the IND approval process with FDA. Our company is rooted in the discoveries of world-renown scientists and ENT surgeons and are now looking for investors to help us build our business development team and establish a strong IP portfolio as we enter into clinical trials.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Missouri
Company HQ Country:
United States
Year Founded:
2011
Main Therapeutic Focus:
Other
Lead Product in Development:
Drug for treating noise-induced hearing loss
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
two to four
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
